title: Chronic myeloid leukemia arising from acute myeloid leukemia: response to imatinib mesylate with favorable outcome.
authors.forename: Xiao-Hua
authors.initials: XH
authors.lastname: Xu
authors.forename: Lian-Sheng
authors.initials: LS
authors.lastname: Huang
authors.forename: Jing
authors.initials: J
authors.lastname: Yang
authors.forename: Teng
authors.initials: T
authors.lastname: Yu
authors.forename: Jie-Feng
authors.initials: JF
authors.lastname: Tong
authors.forename: Xiang-Gui
authors.initials: XG
authors.lastname: Yuan
authors.forename: Xiao-Ying
authors.initials: XY
authors.lastname: Zhao
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D015470:Leukemia, Myeloid, Acute / Q000150:complications*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate